Cargando…

Uncomplicated Diverticular Disease: Innate and Adaptive Immunity in Human Gut Mucosa before and after Rifaximin

Background/Aim. Uncomplicated diverticular disease (UDD) is a frequent condition in adults. The pathogenesis of symptoms remains unknown. Bacteria are able to interact with Toll-like receptors (TLRs) and to induce inflammation through both innate immunity and T-cell recruitment. We investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Cianci, Rossella, Frosali, Simona, Pagliari, Danilo, Cesaro, Paola, Petruzziello, Lucio, Casciano, Fabio, Landolfi, Raffaele, Costamagna, Guido, Pandolfi, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124847/
https://www.ncbi.nlm.nih.gov/pubmed/25133198
http://dx.doi.org/10.1155/2014/696812
_version_ 1782329685223407616
author Cianci, Rossella
Frosali, Simona
Pagliari, Danilo
Cesaro, Paola
Petruzziello, Lucio
Casciano, Fabio
Landolfi, Raffaele
Costamagna, Guido
Pandolfi, Franco
author_facet Cianci, Rossella
Frosali, Simona
Pagliari, Danilo
Cesaro, Paola
Petruzziello, Lucio
Casciano, Fabio
Landolfi, Raffaele
Costamagna, Guido
Pandolfi, Franco
author_sort Cianci, Rossella
collection PubMed
description Background/Aim. Uncomplicated diverticular disease (UDD) is a frequent condition in adults. The pathogenesis of symptoms remains unknown. Bacteria are able to interact with Toll-like receptors (TLRs) and to induce inflammation through both innate immunity and T-cell recruitment. We investigated the pattern of TLRs 2 and 4 and the intestinal homing in patients with UDD before and after a course of Rifaximin. Methods. Forty consecutive patients with UDD and 20 healthy asymptomatic subjects were enrolled. Among UDD patients, 20 were assigned to a 2-month course of treatment with Rifaximin 1.2 g/day for 15 days/month and 20 received placebo. Blood sample and colonic biopsies were obtained from patients and controls. The samples were collected and analyzed at baseline and at the end of treatment. Flow cytometry was performed using monoclonal antibodies (CD3, CD4, CD8, CD103, TCR-gamma/delta, CD14, TLR2, and TLR4). Results. In UDD, TLR2 and TLR4 expression on immune cell subpopulations from blood and mucosa of the affected colon are altered as compared with controls. Rifaximin treatment induced significant modifications of altered conditions. Conclusions. Our data show the role of TLRs in the development of inflammation in UDD. TLRs distribution is altered in UDD and these alterations are reversed after antibiotic treatment. This trial is registered with ClinicalTrials.gov: NCT02068482.
format Online
Article
Text
id pubmed-4124847
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-41248472014-08-17 Uncomplicated Diverticular Disease: Innate and Adaptive Immunity in Human Gut Mucosa before and after Rifaximin Cianci, Rossella Frosali, Simona Pagliari, Danilo Cesaro, Paola Petruzziello, Lucio Casciano, Fabio Landolfi, Raffaele Costamagna, Guido Pandolfi, Franco J Immunol Res Clinical Study Background/Aim. Uncomplicated diverticular disease (UDD) is a frequent condition in adults. The pathogenesis of symptoms remains unknown. Bacteria are able to interact with Toll-like receptors (TLRs) and to induce inflammation through both innate immunity and T-cell recruitment. We investigated the pattern of TLRs 2 and 4 and the intestinal homing in patients with UDD before and after a course of Rifaximin. Methods. Forty consecutive patients with UDD and 20 healthy asymptomatic subjects were enrolled. Among UDD patients, 20 were assigned to a 2-month course of treatment with Rifaximin 1.2 g/day for 15 days/month and 20 received placebo. Blood sample and colonic biopsies were obtained from patients and controls. The samples were collected and analyzed at baseline and at the end of treatment. Flow cytometry was performed using monoclonal antibodies (CD3, CD4, CD8, CD103, TCR-gamma/delta, CD14, TLR2, and TLR4). Results. In UDD, TLR2 and TLR4 expression on immune cell subpopulations from blood and mucosa of the affected colon are altered as compared with controls. Rifaximin treatment induced significant modifications of altered conditions. Conclusions. Our data show the role of TLRs in the development of inflammation in UDD. TLRs distribution is altered in UDD and these alterations are reversed after antibiotic treatment. This trial is registered with ClinicalTrials.gov: NCT02068482. Hindawi Publishing Corporation 2014 2014-07-16 /pmc/articles/PMC4124847/ /pubmed/25133198 http://dx.doi.org/10.1155/2014/696812 Text en Copyright © 2014 Rossella Cianci et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Cianci, Rossella
Frosali, Simona
Pagliari, Danilo
Cesaro, Paola
Petruzziello, Lucio
Casciano, Fabio
Landolfi, Raffaele
Costamagna, Guido
Pandolfi, Franco
Uncomplicated Diverticular Disease: Innate and Adaptive Immunity in Human Gut Mucosa before and after Rifaximin
title Uncomplicated Diverticular Disease: Innate and Adaptive Immunity in Human Gut Mucosa before and after Rifaximin
title_full Uncomplicated Diverticular Disease: Innate and Adaptive Immunity in Human Gut Mucosa before and after Rifaximin
title_fullStr Uncomplicated Diverticular Disease: Innate and Adaptive Immunity in Human Gut Mucosa before and after Rifaximin
title_full_unstemmed Uncomplicated Diverticular Disease: Innate and Adaptive Immunity in Human Gut Mucosa before and after Rifaximin
title_short Uncomplicated Diverticular Disease: Innate and Adaptive Immunity in Human Gut Mucosa before and after Rifaximin
title_sort uncomplicated diverticular disease: innate and adaptive immunity in human gut mucosa before and after rifaximin
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124847/
https://www.ncbi.nlm.nih.gov/pubmed/25133198
http://dx.doi.org/10.1155/2014/696812
work_keys_str_mv AT ciancirossella uncomplicateddiverticulardiseaseinnateandadaptiveimmunityinhumangutmucosabeforeandafterrifaximin
AT frosalisimona uncomplicateddiverticulardiseaseinnateandadaptiveimmunityinhumangutmucosabeforeandafterrifaximin
AT pagliaridanilo uncomplicateddiverticulardiseaseinnateandadaptiveimmunityinhumangutmucosabeforeandafterrifaximin
AT cesaropaola uncomplicateddiverticulardiseaseinnateandadaptiveimmunityinhumangutmucosabeforeandafterrifaximin
AT petruzziellolucio uncomplicateddiverticulardiseaseinnateandadaptiveimmunityinhumangutmucosabeforeandafterrifaximin
AT cascianofabio uncomplicateddiverticulardiseaseinnateandadaptiveimmunityinhumangutmucosabeforeandafterrifaximin
AT landolfiraffaele uncomplicateddiverticulardiseaseinnateandadaptiveimmunityinhumangutmucosabeforeandafterrifaximin
AT costamagnaguido uncomplicateddiverticulardiseaseinnateandadaptiveimmunityinhumangutmucosabeforeandafterrifaximin
AT pandolfifranco uncomplicateddiverticulardiseaseinnateandadaptiveimmunityinhumangutmucosabeforeandafterrifaximin